FUTURE-3 was a prospective, multicenter, single-arm phase II study designed to explore the efficacy and safety of MRI-guided individualized chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. The primary endpoint was one-year progression-free survival rate.
Obtain written informed consent before any trial-related procedures are implemented;
Age 18-80 years;
ECOG performance status score: 0-2 points;
Pathologically confirmed esophageal squamous cell carcinoma;
Enhanced MRI showing a primary esophageal lesion thickness less than 5 mm and a short diameter lymph node less than 1 cm.
Severe emphysema, interstitial lung disease, or COPD.
History of other malignant tumors and chemotherapy within the past 2 years.
History of chest radiotherapy.